BioTime Stock Price and Value Analysis

Should you buy BioTime stock? (NYSE American:BTX). Let's see how it does in our automated value investing analysis system.

BTX Free Cash Flow Trend

Free Cash Flow trendline for BTX
Free Cash Flow trendline for BioTime

Hmm, we can't give any reliable projection for BioTime's growth rate. The company either has too few years of historical data for us to examine, or it's in the habit of losing money.

None of this means it's a bad stock. Maybe it's new and growing quickly, or maybe it's turning things around. We can't say anything sensible about it, so we won't say it's obviously undervalued right now. Proceed at your own risk!

AdvantagesDisadvantagesNeutral
  • This company has amazingly consistent growth!
  • This company is solid.
  • This stock looks overpriced.
  • This company is not making money.
  • This company pays no dividend.

Inside the BTX Numbers

BTX Price
(BioTime stock price per share)
$0.92
[?] PE Ratio versus Sector 80% lower than other Healthcare stocks
[?] PE Ratio versus Industry 93% lower than other Biotechnology stocks
[?] Cash Yield -16.35%
[?] Free Cash Flow Jitter 11%

Is BioTime Stock on Sale?

Based on our analysis, we believe that you should not buy BioTime right now. It might be a good stock to own—we just can't prove it with value analysis right now. Proceed with caution.

Should You Buy BTX Stock?

Does BioTime have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.